Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ring vaccination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Ring vaccination. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-001512-28 Sponsor Protocol Number: COVIM Start Date*: 2021-05-11
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations
    Medical condition: SARS-CoV-2 immunogenicity
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002362-66 Sponsor Protocol Number: 111738 Start Date*: 2008-09-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, observer-blind, multi-country, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals FLU NG vaccine compared to the referenc...
    Medical condition: Immunization against influenza in male and female subjects aged 66 years or older and 19-43 years of age.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010811-34 Sponsor Protocol Number: 113018 Start Date*: 2009-04-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 year...
    Medical condition: Immunization against influenza of healthy adults.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001310-24 Sponsor Protocol Number: 111631 Start Date*: 2008-05-30
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ / Influsplit SSW® 2008/2009 injected intramuscularly in young adults (18 to 60 ye...
    Medical condition: Immunization against influenza of healthy adults.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019532-12 Sponsor Protocol Number: CSLCT-ASU-10-66 Start Date*: 2010-04-22
    Sponsor Name:CSL Limited
    Full Title: A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of the Enzira® vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged 18 to 5...
    Medical condition: Prophylaxis of influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059429 Influenza immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002360-33 Sponsor Protocol Number: 111737 Start Date*: 2008-08-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to ...
    Medical condition: Immunization against influenza in male and female subjects aged 18-41 years and 65 years or older.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003248-31 Sponsor Protocol Number: 110806 Start Date*: 2007-11-16
    Sponsor Name:GSK Biologicals
    Full Title: An open, phase IV, non-randomised, single-centre study with two study groups to assess the immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced...
    Medical condition: Booster vaccination against diphtheria, tetanus and pertussis diseases in adults
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-003477-94 Sponsor Protocol Number: 110947 Start Date*: 2008-02-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellu...
    Medical condition: Booster immunisation against diphtheria, tetanus, pertussis and poliomyelitis diseases in children and adolescents.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001445-26 Sponsor Protocol Number: 110627 Start Date*: 2008-05-30
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval t...
    Medical condition: Immunization against influenza of healthy adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000035-23 Sponsor Protocol Number: VLA2001-307 Start Date*: 2022-04-11
    Sponsor Name:Valneva Austria GmbH
    Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI...
    Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001239-38 Sponsor Protocol Number: CP-PRO-QVLP-012 Start Date*: 2017-10-23
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64...
    Medical condition: Seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007876-41 Sponsor Protocol Number: 111567 Start Date*: 2008-03-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals...
    Medical condition: Cervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004582-27 Sponsor Protocol Number: RSV-MVA-013 Start Date*: 2018-07-23
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A Phase 2a Randomized, Double-blinded, Placebo-controlled Trial to assess the Safety, Immunogenicity, and Efficacy of the recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infectio...
    Medical condition: Upper and lower respiratory tract infections caused by Respiratory Syncytical Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004711-35 Sponsor Protocol Number: 112147 Start Date*: 2008-10-07
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: Estudio de vacunación, fase III, observador ciego, aleatorizado (3:3:2), control activo, multinacional, multicéntrico para evaluar la respuesta inmune celular y humoral de la vacuna FLU NG de GSK B...
    Medical condition: Inmunización frente a la gripe estacional de varones y mujeres de 65 años y mayores o de 18 a 40 años Immunization against seasonal influenza in men and woman aged 65 years and older or 18 to 40 y...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012117-21 Sponsor Protocol Number: 112682 Start Date*: 2009-09-29
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in adolesce...
    Medical condition: Antibody persistence and hepatitis B vaccine challenge in adolescents aged 12-13 years, vaccinated in infancy with three doses of GSK Biologicals’ HBV vaccine in routine practice.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001507-31 Sponsor Protocol Number: 111535 Start Date*: 2015-06-09
    Sponsor Name:GlaxoSmithKline Biologicals - GSK China Vaccines
    Full Title: A phase IIIb, open-label, multicentre study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ combined diphtheria-tetanus-acellular pertussis (DTPa)- Haemophilus influen...
    Medical condition: Healthy volunteers (Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis and Haemophilus influenzae type b diseases).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005509-28 Sponsor Protocol Number: 901452-CT-21-001 Start Date*: 2022-02-10
    Sponsor Name:Akston Biosciences Corporation
    Full Title: Anti-COVID19 VaccinaTion AKS-452X BOOSTER Study (ACT-BOOSTER study)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004853-34 Sponsor Protocol Number: CT1401-B Start Date*: 2017-05-04
    Sponsor Name:Dalhousie University
    Full Title: A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adult...
    Medical condition: Ebola is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebola virus species, four of which are known to cause disease in humans: Ebola virus...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10014074 Ebola virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-004455-29 Sponsor Protocol Number: 112115 Start Date*: 2008-12-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination wi...
    Medical condition: Hepatitis B surface antigen (HBsAg) vaccine administred in HBV naïve adult subjects aged between 18 and 45 years old, inclusive, in good general health.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005997-82 Sponsor Protocol Number: 900452-CT-20-001 Start Date*: 2021-03-12
    Sponsor Name:UMCG
    Full Title: Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study (ACT-study)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 23:50:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA